A Phase 1, Non-randomized, Open-label, Single Dose Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics, Safety And Tolerability Of Rivipansel (Pf-06460031) In Subjects With Renal Impairment And In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Rivipansel (Primary)
- Indications Haematological malignancies; Sickle cell anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 05 Mar 2018 Status changed from recruiting to completed.
- 22 Feb 2018 Planned End Date changed from 1 Feb 2018 to 21 Feb 2018.
- 22 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 21 Feb 2018.